BRAF and neoplasm: It should also be noted that miR-146b deregulation was associated with aggressive tumor behavior in BRAF-positive clinical PTC specimens (105) and that patients with BRAF mutations exhibited increased miR-146b expression in comparison to BRAF wild-type controls (106).